Artigos de revistas sobre o tema "Immune check point inhibitor"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Immune check point inhibitor".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
Jaswani, Tamika S., Meeta Desai, Douglas Grider e Jonathan M. Bern. "Immune Check Point Inhibitor-induced Colitis". American Journal of Gastroenterology 112 (outubro de 2017): S858—S860. http://dx.doi.org/10.14309/00000434-201710001-01575.
Texto completo da fonteBobart, Shane A., Itunu Owoyemi, Joseph Grande, Nelson Leung e Sandra M. Herrmann. "Immune Check Point Inhibitor–Associated Endothelialitis". Kidney International Reports 5, n.º 8 (agosto de 2020): 1371–74. http://dx.doi.org/10.1016/j.ekir.2020.05.027.
Texto completo da fonteAshour, Tarek, Georges Nakhoul, Pradnya Patil, Pauline Funchain e Leal Herlitz. "Immune Check Point Inhibitor–Associated Glomerulonephritis". Kidney International Reports 4, n.º 2 (fevereiro de 2019): 355–59. http://dx.doi.org/10.1016/j.ekir.2018.10.017.
Texto completo da fonteKumar, Aswini, Maximilian Lee e Talhat Azemi. "IMMUNE CHECK POINT INHIBITOR MYOCARDITIS MIMICKING ACS". Journal of the American College of Cardiology 73, n.º 9 (março de 2019): 2681. http://dx.doi.org/10.1016/s0735-1097(19)33287-5.
Texto completo da fonteNilajgi, Shalini, Nicholas Kasmeridis e Kichendasse Ganessan. "A Case Of Immune Check Point Inhibitor - Induced Hypophysitis". Journal of the Endocrine Society 5, Supplement_1 (1 de maio de 2021): A560. http://dx.doi.org/10.1210/jendso/bvab048.1142.
Texto completo da fonteSuchý, David. "Immune-related adverse events associated with immune check-point inhibitors". Klinická farmakologie a farmacie 33, n.º 3 (28 de outubro de 2019): 20–24. http://dx.doi.org/10.36290/far.2019.019.
Texto completo da fonteMarthey, Lysiane, Raef Abdallah, Christophe Bellanger, Clément Bresteau, Antoine Meyer, Aurélien Amiot e Franck Carbonnel. "Immune check-point inhibitors related enterocolitis". Hépato-Gastro & Oncologie Digestive 30, n.º 8 (outubro de 2023): 826–32. http://dx.doi.org/10.1684/hpg.2023.2641.
Texto completo da fonteJohncilla, Melanie, Shilpa Grover, Xuchen Zhang, Dhanpat Jain e Amitabh Srivastava. "Morphological spectrum of immune check‐point inhibitor therapy‐associated gastritis". Histopathology 76, n.º 4 (18 de fevereiro de 2020): 531–39. http://dx.doi.org/10.1111/his.14029.
Texto completo da fonteKim, Jin Young, Chi Heum Cho e Hong Suk Song. "Targeted therapy of ovarian cancer including immune check point inhibitor". Korean Journal of Internal Medicine 32, n.º 5 (1 de setembro de 2017): 798–804. http://dx.doi.org/10.3904/kjim.2017.008.
Texto completo da fonteVergne-Santiago, Norma, Ernesto Jos E. Sola Sanchez e Michelle Marie Mangual Garcia. "Immune Check Point Inhibitors Triggering Non Autoimmune Polyendocrinopathy". Journal of the Endocrine Society 5, Supplement_1 (1 de maio de 2021): A136—A137. http://dx.doi.org/10.1210/jendso/bvab048.275.
Texto completo da fonteKorotaeva, A. A., N. V. Apanovich, E. A. Braga, V. B. Matveev e A. V. Karpukhin. "Current advances in kidney cancer immunotherapy". Cancer Urology 15, n.º 4 (16 de janeiro de 2020): 30–38. http://dx.doi.org/10.17650/1726-9776-2019-15-4-30-38.
Texto completo da fonteMaster, Samip R., Arelis Robinson, Glenn Morris Mills e Richard P. Mansour. "Cardiovascular complications of immune checkpoint inhibitor therapy." Journal of Clinical Oncology 37, n.º 15_suppl (20 de maio de 2019): 2568. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.2568.
Texto completo da fonteDurno, Carol A., Melyssa Aronson, Melissa Edwards, Simon Ling, Valérie Larouche, Annika Bronsema, Michael Osborn et al. "Immune Check Point Inhibitor Treatment for Young Patients with Hypermutant Cancers". Gastroenterology 152, n.º 5 (abril de 2017): S141. http://dx.doi.org/10.1016/s0016-5085(17)30801-6.
Texto completo da fonteAlbert, Stewart, Gouyu Ling, Srikanth Nadella e Aparna Yeggalam. "ODP170 Check Point Inhibitor Associated Multi-Endocrine Dysfunction Presenting With Euglycemic Ketoacidosis". Journal of the Endocrine Society 6, Supplement_1 (1 de novembro de 2022): A71—A72. http://dx.doi.org/10.1210/jendso/bvac150.148.
Texto completo da fonteKapoor, Vidit, e Olivier Rixe. "Toxicity of PD-1/CTLA-4 inhibitor immunotherapy among elderly patients." Journal of Clinical Oncology 37, n.º 15_suppl (20 de maio de 2019): e14139-e14139. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14139.
Texto completo da fonteSchmidinger, Manuela, Irene Resch, Harun Fajkovic, Mesut Remzi, Shahrokh F. Shariat e Jens Bedke. "Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma?" Current Opinion in Urology 31, n.º 3 (11 de março de 2021): 270–75. http://dx.doi.org/10.1097/mou.0000000000000874.
Texto completo da fonteThomas, Richard, Bibin Sebastian, Tom George, Noor Fatima Majeed, Temilola Akinola, Shawn L. Laferriere e Marta Braschi-Amirfarzan. "A review of the imaging manifestations of immune check point inhibitor toxicities". Clinical Imaging 64 (agosto de 2020): 70–79. http://dx.doi.org/10.1016/j.clinimag.2020.04.007.
Texto completo da fonteMbaraonye, Uchenne, Lily Romero Karam, Cindy Nguyen, Deepa Gotur e Simon Yau. "IMMUNE CHECK POINT INHIBITOR-INDUCED ORGANIZING PNEUMONIA IN A LUNG TRANSPLANT PATIENT". Chest 158, n.º 4 (outubro de 2020): A1135—A1136. http://dx.doi.org/10.1016/j.chest.2020.08.1038.
Texto completo da fonteArcari, Luca, Giacomo Tini, Giovanni Camastra, Federica Ciolina, Domenico De Santis, Domitilla Russo, Damiano Caruso, Massimiliano Danti e Luca Cacciotti. "Cardiac Magnetic Resonance Imaging in Immune Check-Point Inhibitor Myocarditis: A Systematic Review". Journal of Imaging 8, n.º 4 (5 de abril de 2022): 99. http://dx.doi.org/10.3390/jimaging8040099.
Texto completo da fonteMathew Thomas, Vinay, Poorva Bindal, Swetha Ann Alexander e Kymberly McDonald. "Nivolumab-induced hepatitis: A rare side effect of an immune check point inhibitor". Journal of Oncology Pharmacy Practice 26, n.º 2 (25 de março de 2019): 459–61. http://dx.doi.org/10.1177/1078155219837342.
Texto completo da fonteDas, Undurti N. "Bioactive lipids as modulators of immune check point inhibitors". Medical Hypotheses 135 (fevereiro de 2020): 109473. http://dx.doi.org/10.1016/j.mehy.2019.109473.
Texto completo da fonteLleo, Ana, Lorenza Rimassa e Massimo Colombo. "Hepatotoxicity of immune check point inhibitors: Approach and management". Digestive and Liver Disease 51, n.º 8 (agosto de 2019): 1074–78. http://dx.doi.org/10.1016/j.dld.2019.06.017.
Texto completo da fonteKiyota, Naomi. "Immune check point inhibitors for head and neck cancer". Toukeibu Gan 44, n.º 4 (2018): 336–41. http://dx.doi.org/10.5981/jjhnc.44.336.
Texto completo da fonteSørensen, A. S., M. Nørgaard Andersen, K. Juul-Madsen, C. Skejø, H. Schmidt, T. Vorup-Jensen e T. W. Kragstrup. "OP0130 IN VITRO CHARACTERIZATION OF INFLAMMATORY ARTHRITIS ASSOCIATED WITH IMMUNE CHECK POINT INHIBITION". Annals of the Rheumatic Diseases 79, Suppl 1 (junho de 2020): 85.1–85. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1356.
Texto completo da fonteMudunov, A. M., A. V. Ignatova, A. S. Morozova, S. O. Podvyaznikov e Yu V. Alymov. "Combination of concurrent targeted and immune-therapy with nivolumab and cetuximab: new perspectives for squamous cell carcinoma treatment". Head and Neck Tumors (HNT) 10, n.º 3 (16 de novembro de 2020): 111–17. http://dx.doi.org/10.17650/2222-1468-2020-10-3-111-117.
Texto completo da fonteElkayam, Natalie, e Shaurya Sharma. "Dual checkpoint inhibitor induced autoimmune encephalitis". Archive of Oncology 25, n.º 2 (2019): 22–24. http://dx.doi.org/10.2298/aoo181230003e.
Texto completo da fonteTaylor, C., M. Reno e D. Sharma. "Secondary sclerosing cholangitis: a lesser known side effect of pembrolizumab therapy". American Journal of Clinical Pathology 156, Supplement_1 (1 de outubro de 2021): S123—S124. http://dx.doi.org/10.1093/ajcp/aqab191.263.
Texto completo da fonteIbraheim, Hajir, Esperanza Perucha e Nick Powell. "Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors". Rheumatology 58, Supplement_7 (1 de dezembro de 2019): vii17—vii28. http://dx.doi.org/10.1093/rheumatology/kez465.
Texto completo da fonteDrommi, Fabiana, Alessia Calabrò, Grazia Vento, Gaetana Pezzino, Riccardo Cavaliere, Fausto Omero, Paola Muscolino et al. "Crosstalk between ILC3s and Microbiota: Implications for Colon Cancer Development and Treatment with Immune Check Point Inhibitors". Cancers 15, n.º 11 (24 de maio de 2023): 2893. http://dx.doi.org/10.3390/cancers15112893.
Texto completo da fonteKeyes, Erin, Muhammad B. Hammami e Kendall R. Beck. "2555 Immune Check Point Inhibitor Enteritis: A Case of Severe Duodenitis From Nivolumab Therapy". American Journal of Gastroenterology 114, n.º 1 (outubro de 2019): S1405. http://dx.doi.org/10.14309/01.ajg.0000599752.28233.77.
Texto completo da fonteSanchez, Carlos A. Vergara, Rashid Alhusain, Jordan Christopher Ray e Julio Perez-Downes. "A CASE OF IMMUNE CHECK POINT INHIBITOR MEDIATED MYOPERICARDITIS: MANAGING A RARE ADVERSE REACTION". Journal of the American College of Cardiology 83, n.º 13 (abril de 2024): 3204. http://dx.doi.org/10.1016/s0735-1097(24)05194-5.
Texto completo da fonteAlbarel, Frédérique, Frédéric Castinetti e Thierry Brue. "MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis". European Journal of Endocrinology 181, n.º 3 (setembro de 2019): R107—R118. http://dx.doi.org/10.1530/eje-19-0169.
Texto completo da fonteSoares, Adriana, Rafael Carmo, Catarina Rodrigues, Inês Teles Grilo e Enrique Grande. "Chemotherapy Plus Immune Check-Point Inhibitors in Metastatic Bladder Cancer". Bladder Cancer 6, n.º 1 (28 de março de 2020): 1–8. http://dx.doi.org/10.3233/blc-190260.
Texto completo da fonteOrloff, Marlana, Ryan Weight, Matias E. Valsecchi e Takami Sato. "Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?" Reviews on Recent Clinical Trials 11, n.º 2 (1 de maio de 2016): 81–86. http://dx.doi.org/10.2174/1574887111666160330120712.
Texto completo da fonteKiyota, Naomi. "Current status of immune check point inhibitors for solid malignancy". Annals of Oncology 27 (novembro de 2016): vii5. http://dx.doi.org/10.1093/annonc/mdw453.
Texto completo da fonteStruble, Roger, Vikas Koppurapu, Derek Hupp, Yana Zemkova, Andrei Schwartz, Jeff Wilson e Charles Rappaport. "YIELD OF BAL IN PATIENTS RECEIVING IMMUNE CHECK POINT INHIBITORS". Chest 158, n.º 4 (outubro de 2020): A1935. http://dx.doi.org/10.1016/j.chest.2020.08.1675.
Texto completo da fonteGupta, Tarana, e Nikhil Sai Jarpula. "Hepatocellular carcinoma immune microenvironment and check point inhibitors-current status". World Journal of Hepatology 16, n.º 3 (27 de março de 2024): 353–65. http://dx.doi.org/10.4254/wjh.v16.i3.353.
Texto completo da fonteM. Guirgis, Helmy. "The Impact of The Immune Check Point Duration of use on Cost in Lung Cancer". Pharmaceutics and Pharmacology Research 5, n.º 6 (30 de maio de 2022): 01–05. http://dx.doi.org/10.31579/2693-7247/086.
Texto completo da fonteChintalacheruvu, Lakshmi Manogna, Kushal Naha, Vamsi Krishna Chilluru e Donald C. Doll. "Review of neurological side effects associated with checkpoint inhibitor therapy in cancer patients." Journal of Clinical Oncology 38, n.º 5_suppl (10 de fevereiro de 2020): 72. http://dx.doi.org/10.1200/jco.2020.38.5_suppl.72.
Texto completo da fontekazuhiro, S., K. Sugiyama, K. Nozawa, Y. Funahashi, Y. Kogure, C. Kitagawa, S. Ichihara, R. Nishimura, T. Kubota e H. Saka. "Single-institute, retrospective study of metastatic uveal melanoma in the immune check point inhibitor era". Annals of Oncology 29 (novembro de 2018): ix106. http://dx.doi.org/10.1093/annonc/mdy439.005.
Texto completo da fonteMalkova, A. M., R. V. Orlova, N. V. Zhukova, A. R. Gubal e V. V. Sharoiko. "Analysis of possible markers of effective antitumor cellular immune response before starting therapy with immune check-point inhibitors". Siberian journal of oncology 21, n.º 2 (8 de maio de 2022): 109–17. http://dx.doi.org/10.21294/1814-4861-2022-21-2-109-117.
Texto completo da fonteRevathi, Duraisamy, Ganapathy Dhanraj e V. Ashok. "Immune check point inhibitors: A promising therapeutic approach in oral cancer". Oral Oncology 132 (setembro de 2022): 105977. http://dx.doi.org/10.1016/j.oraloncology.2022.105977.
Texto completo da fonteKhamnueva, L. Yu Khamnueva, K. A. Sergeeva Sergeeva, L. S. Andreeva Andreeva e A. V. Davydova Davydova. "Endocrinopathies induced by immune check point inhibitors. Optimal patient management tactics". Pharmateca 12_2020 (23 de novembro de 2020): 8–13. http://dx.doi.org/10.18565/pharmateca.2020.12.8-13.
Texto completo da fonteStringer, Bryan F., Nikhila Kethireddy, Alain Rizkallah e Konstadina Darsaklis. "MYOCARDITIS SECONDARY TO IMMUNE CHECK-POINT INHIBITORS: DIFFICULTIES IN ARRHYTHMIA MANAGEMENT". Journal of the American College of Cardiology 75, n.º 11 (março de 2020): 2694. http://dx.doi.org/10.1016/s0735-1097(20)33321-0.
Texto completo da fonteMuhailan, Mohamad, e Ghassan Al-Shbool. "Pseudo-Wellens’ Syndrome Temporally Associated With Immune Check Point Inhibitors Use". American Journal of the Medical Sciences 359, n.º 1 (janeiro de 2020): e1-e2. http://dx.doi.org/10.1016/j.amjms.2019.07.006.
Texto completo da fonteKim, Hyunseok, Soyeon Ahn, Hyungjin Kwon, Hsuan-Ju Chen, Inwon Park, Pilhan Kim e Akyildiz Kubra. "Abstract 2397: An advanced approach technique for tracking point between immune check point inhibitor and cancer cell mechanism in immune response motility by infiltration a breast cancer cell". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 2397. http://dx.doi.org/10.1158/1538-7445.am2023-2397.
Texto completo da fonteRoy, Arya Mariam, e Saby George. "Emerging resistance vs. losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena". Cancer Drug Resistance 6, n.º 3 (20 de setembro de 2023): 642–55. http://dx.doi.org/10.20517/cdr.2023.47.
Texto completo da fonteFurnish, Robin, Heather Bear, Xin Wei e Timothy Phoenix. "MODL-29. EVALUATING TUMOR-IMMUNE INTERACTIONS IN MOUSE MODELS OF DIFFUSE INTRINSIC PONTINE GLIOMA". Neuro-Oncology 22, Supplement_3 (1 de dezembro de 2020): iii417. http://dx.doi.org/10.1093/neuonc/noaa222.602.
Texto completo da fonteDe Felice, Francesca, Daniela Musio e Vincenzo Tombolini. "Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment". Journal of Personalized Medicine 11, n.º 5 (10 de maio de 2021): 393. http://dx.doi.org/10.3390/jpm11050393.
Texto completo da fonteKikuchi, Yoshihiro, Hiroko Kouta, Takayoshi Asakawa, Miyuki Horikoshi, Tomoyuki Yoshikawa, Masashi Takano e Kenichi Furuya. "Roles of an immune-check point inhibitor (nivolumab) in heavily pretreated and platinum-resistant gynecologic cancers." Journal of Clinical Oncology 36, n.º 15_suppl (20 de maio de 2018): e17562-e17562. http://dx.doi.org/10.1200/jco.2018.36.15_suppl.e17562.
Texto completo da fonte